Clinical Trial Update: Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer [Phase 1]

View source ↗

Summary

This update reports the completion of a Phase 1 safety study evaluating GL-ONC1, an attenuated vaccinia virus, in combination therapy for head and neck cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• GL-ONC1

Snippet

Sponsor: Genelux Corporation | Conditions: Cancer of Head and Neck | Phase 1 | Status: COMPLETED